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A case of mistaken identity --- 
Biomarkers for high risk premalignant 
breast lesions 
breastcancer.org 
Estimated costs: $20,000 to 
$100,000/patient. 
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Atypical hyperplasias 
Progression to invasive cancer 
50,000 new  
cases annually 
Expect 10,000 new  
cases annually 
Up to $1B to treat 
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Subtypes of lesions with 
malignant potential 
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Data Manager 
• Collate data 
• Provides summary data 
• Extract data from clinical 
  records 
• Coded data for 
   IRB-approved projects  
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Atypical hyperplasia (UMMS 1999-2003) 
2833 breast core biopsies 
120 with primary diagnosis of ADH 
Upstaging upon re-excision 
12 
Summary 
• Value of diagnostic test 
– Large interobserver variability in diagnosing 
premalignant lesions (Jain et al., 2011. PMID 
21532546) 
– Identify subgroups to benefit from preventive therapies.  
– Identify molecular pathways to provide appropriate 
preventive treatments 
• Technical challenges 
– Minute amounts of tissue 
– Fragmentation of RNA in FFPE tissues 
– Amplification and labeling for robust detection 
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